1. Home
  2. ANAB vs GABC Comparison

ANAB vs GABC Comparison

Compare ANAB & GABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$60.37

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo German American Bancorp Inc.

GABC

German American Bancorp Inc.

HOLD

Current Price

$43.00

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
GABC
Founded
2005
1910
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
ANAB
GABC
Price
$60.37
$43.00
Analyst Decision
Buy
Buy
Analyst Count
12
3
Target Price
$71.67
$47.67
AVG Volume (30 Days)
586.1K
78.2K
Earning Date
05-08-2026
04-27-2026
Dividend Yield
N/A
2.88%
EPS Growth
91.02
8.13
EPS
N/A
0.88
Revenue
$234,603,000.00
$487,401,000.00
Revenue This Year
N/A
$16.78
Revenue Next Year
$52.14
$3.98
P/E Ratio
N/A
$48.51
Revenue Growth
157.01
37.80
52 Week Low
$17.11
$36.65
52 Week High
$73.30
$45.00

Technical Indicators

Market Signals
Indicator
ANAB
GABC
Relative Strength Index (RSI) 44.74 54.62
Support Level $53.46 $42.34
Resistance Level $67.69 $44.68
Average True Range (ATR) 4.38 0.88
MACD -0.93 -0.08
Stochastic Oscillator 19.86 68.54

Price Performance

Historical Comparison
ANAB
GABC

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About GABC German American Bancorp Inc.

German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.

Share on Social Networks: